These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9085628)

  • 21. [DRUG-INDUCED LIVER INJURY AND PYRAZINAMIDE USE].
    Horita N; Miyazawa N
    Kekkaku; 2015 Mar; 90(3):401-5. PubMed ID: 26477109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rifampicin/pyrazinamide therapy should not be used for latent tuberculosis infection.
    Garca-Doval I
    J Am Acad Dermatol; 2004 May; 50(5):801; author reply 801-2. PubMed ID: 15097974
    [No Abstract]   [Full Text] [Related]  

  • 23. [Liver injury under tuberculostatic treatment].
    Fattinger K; Braunschweig S; Reichen J; Meier-Abt PJ; Krähenbühl S
    Praxis (Bern 1994); 1997 Apr; 86(15):626-9. PubMed ID: 9213916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Severe hepatotoxicity of tuberculostatic agents. Increase in the incidence].
    Moitinho E; Salmerón JM; Mas A; Bruguera M; Rodés J
    Gastroenterol Hepatol; 1996 Nov; 19(9):448-51. PubMed ID: 8998667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.
    Bouazzi OE; Hammi S; Bourkadi JE; Tebaa A; Tanani DS; Soulaymani-Bencheikh R; Badrane N; Bengueddour R
    Pan Afr Med J; 2016; 25():167. PubMed ID: 28292129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.
    Ohkawa K; Hashiguchi M; Ohno K; Kiuchi C; Takahashi S; Kondo S; Echizen H; Ogata H
    Clin Pharmacol Ther; 2002 Aug; 72(2):220-6. PubMed ID: 12189369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From the Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
    JAMA; 2001 May 23-30; 285(20):2572-3. PubMed ID: 11396466
    [No Abstract]   [Full Text] [Related]  

  • 28. Drugs for tuberculosis.
    Med Lett Drugs Ther; 1988 Apr; 30(763):43-4. PubMed ID: 3352531
    [No Abstract]   [Full Text] [Related]  

  • 29. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinically apparent liver damage during brief tuberculosis therapy].
    Estay S; Armas Merino R; Vega C; Soto JR
    Rev Med Chil; 1981 Oct; 109(10):941-4. PubMed ID: 7344017
    [No Abstract]   [Full Text] [Related]  

  • 31. Antitubercular drugs (isoniazid, rifampin and pyrazinamide): hepatobiliary reactions.
    Vu D; Macdonald L
    CMAJ; 2001 Oct; 165(7):942-3, 946-7. PubMed ID: 11599338
    [No Abstract]   [Full Text] [Related]  

  • 32. Influence of diabetes on liver injury induced by antitubercular drugs and on silymarin hepatoprotection in rats.
    Srivastava RK; Sharma S; Verma S; Arora B; Lal H
    Methods Find Exp Clin Pharmacol; 2008 Dec; 30(10):731-7. PubMed ID: 19271021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
    JAMA; 2001 Sep; 286(12):1445-6. PubMed ID: 11596606
    [No Abstract]   [Full Text] [Related]  

  • 34. Enlarged cervical lymph nodes and elevated liver chemistry tests: a therapeutic dilemma.
    Dietrich CG; Gartung C; Lorenzen J; Geier A; Wasmuth HE; Matern S; Lammert F
    Ann Hepatol; 2004; 3(3):118-20. PubMed ID: 15505599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antituberculosis drugs and hepatotoxicity.
    Sharma SK
    Infect Genet Evol; 2004 Jun; 4(2):167-70. PubMed ID: 15157635
    [No Abstract]   [Full Text] [Related]  

  • 36. Liver injury during antituberculosis treatment: an 11-year study.
    Døssing M; Wilcke JT; Askgaard DS; Nybo B
    Tuber Lung Dis; 1996 Aug; 77(4):335-40. PubMed ID: 8796249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pyrazinamide-induced granulomatous hepatitis.
    Knobel B; Buyanowsky G; Dan M; Zaidel L
    J Clin Gastroenterol; 1997 Jun; 24(4):264-6. PubMed ID: 9252856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
    Jasmer RM; Daley CL
    Am J Respir Crit Care Med; 2003 Mar; 167(6):809-10. PubMed ID: 12623855
    [No Abstract]   [Full Text] [Related]  

  • 39. Hepatotoxicity to different antituberculosis drug combinations.
    Aziz S; Agha F; Hassan R; Fairoz SA; Hassan K
    J Pak Med Assoc; 1990 Dec; 40(12):290-4. PubMed ID: 2126569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. From the Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    JAMA; 2002 Dec; 288(23):2967. PubMed ID: 12492097
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.